share_log

424B3: Prospectus

424B3: Prospectus

424B3:募资说明书
美股SEC公告 ·  08/19 17:03

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. has filed a Form 8-K with the SEC, disclosing non-compliance with Nasdaq's continued listing requirements. Specifically, the company's market value of publicly held shares and market value of listed securities fell below the minimum thresholds. Conduit has 180 days to regain compliance. Additionally, undisclosed dispositions of substantial company shares by a director and a significant stockholder's shares being under third-party pledge were discovered. The board has formed a Special Committee and a Trading Review Committee to investigate and address these issues.
Conduit Pharmaceuticals Inc. has filed a Form 8-K with the SEC, disclosing non-compliance with Nasdaq's continued listing requirements. Specifically, the company's market value of publicly held shares and market value of listed securities fell below the minimum thresholds. Conduit has 180 days to regain compliance. Additionally, undisclosed dispositions of substantial company shares by a director and a significant stockholder's shares being under third-party pledge were discovered. The board has formed a Special Committee and a Trading Review Committee to investigate and address these issues.
Conduit Pharmaceuticals Inc.已向美国证券交易委员会提交了8-K表格,披露未遵守纳斯达克持续上市要求,具体来说,公司公开持股市值和上市证券市值均低于最低阈值。 Conduit有180天恢复符合条件。 此外,董事未公开出售大量公司股份,并发现大股东的股份被第三方质押。 董事会已成立特别委员会和交易审查委员会调查和解决这些问题。
Conduit Pharmaceuticals Inc.已向美国证券交易委员会提交了8-K表格,披露未遵守纳斯达克持续上市要求,具体来说,公司公开持股市值和上市证券市值均低于最低阈值。 Conduit有180天恢复符合条件。 此外,董事未公开出售大量公司股份,并发现大股东的股份被第三方质押。 董事会已成立特别委员会和交易审查委员会调查和解决这些问题。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息